Document Detail


Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
MedLine Citation:
PMID:  7673616     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The acid-inhibitory effect of lansoprazole was evaluated in comparison with that of famotidine and omeprazole by using 24-h intragastric pH monitoring in 10 young, healthy Japanese volunteers. Lansoprazole 20 mg once daily in the morning was superior to famotidine 20 mg twice daily, omeprazole 20 mg once daily in the morning in reducing 24-h intragastric acidity. Unlike famotidine, whose acid-inhibitory effect was observed mainly at night, both lansoprazole and omeprazole inhibited both daytime and nocturnal acid secretion, with the maximal effect occurring in the afternoon. Although the daily profile of acid-inhibitory action of lansoprazole was similar to that of omeprazole, the acid-inhibitory effect of lansoprazole was more potent than that of omeprazole at any time of the day. These results indicate that lansoprazole at a dosage of 30 mg once daily in the morning produced the most potent inhibition of acid secretion in young Japanese volunteers, compared with famotidine 20 mg twice daily and omeprazole 20 mg once in the morning.
Authors:
H Takeda; K Hokari; M Asaka
Related Documents :
11729446 - Impact of acid-related disorders in the united states.
3775216 - Action of calcium channel inhibitors on acid gastric secretion in ulcer patients.
2260736 - Basal and pentagastrin-stimulated gastric secretion in young horses.
1574606 - Fluoxetine pretreatment potentiates intracisternal trh analogue-stimulated gastric acid...
21214246 - Hypochlorous and peracetic acid induced oxidation of dairy proteins.
6474106 - Chronic effects of trichloroethylene upon s-100 protein content and lipid composition i...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  20 Suppl 1     ISSN:  0192-0790     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  1995  
Date Detail:
Created Date:  1995-10-17     Completed Date:  1995-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S7-9     Citation Subset:  IM    
Affiliation:
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Administration, Oral
Adult
Anti-Ulcer Agents / administration & dosage,  pharmacology*
Famotidine / pharmacology*
Gastric Acid / secretion*
Gastric Acidity Determination
Gastric Mucosa / drug effects*,  secretion
Humans
Hydrogen-Ion Concentration
Male
Monitoring, Physiologic
Omeprazole / administration & dosage,  analogs & derivatives*,  pharmacology*
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole; 73590-58-6/Omeprazole; 76824-35-6/Famotidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Next Document:  Conservative therapy of plantar puncture wounds.